(Q42926668)

11 November 2017

A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

11 November 2017

1 reference

1 reference

Farhad Soltani

1

1 reference

11 November 2017

Mehdi Sayyah

2

1 reference

11 November 2017

Fariba Feizy

3

1 reference

11 November 2017

Alireza Malayeri

4

1 reference

11 November 2017

Amir Siahpoosh

5

1 reference

11 November 2017

Ismail Motlagh

6

1 reference

11 November 2017

1 August 2010

1 reference

11 November 2017

Human Psychopharmacology

1 reference

11 November 2017

25

1 reference

11 November 2017

509-513

1 reference

11 November 2017

6

1 reference

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

11 November 2017

1 reference

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters

21 January 2018

1 reference

7 January 2021

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

1 reference

7 January 2021

Serotonin and the GI tract

1 reference

7 January 2021

Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.

1 reference

7 January 2021

Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function.

1 reference

7 January 2021

Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder

1 reference

7 January 2021

Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial

1 reference

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

7 January 2021

Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study

1 reference

7 January 2021

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

1 reference

7 January 2021

Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran)

1 reference

7 January 2021

5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors

1 reference

7 January 2021

Obsessive compulsive disorder: Opportunities within and beyond the serotonergic domain

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1145

1 reference

11 November 2017

1 reference